You are here:
Trulicity
Extension of indication to include treatment of type 2 diabetes mellitus (T2DM) in children and adolescents aged 10 to less than 18 years
No estimate possible yet
Registration application pending
Dulaglutide
Metabolism and Endocrinology
Indication extension
Diabetes
Eli Lilly
Intramuscular
Injection
Extramural (GVS)
GLP1-agonist
Centralised (EMA)
Normal trajectory
No
July 2022
May 2023
NCT02963766
Participants received 0,75mg/week or 1,5 mg/week dulaglutide administered SC for 26 weeks during the double-blind period and open-label 1,5mg/week for 26 weeks during the study.
There is currently nothing known about the expected patient volume.
< € 802.00
GIPdatabank
In 2021 werd er per volwassen gebruiker €802,20 vergoed.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines